

# Effects of Nonpolar Mutations in Each of the Seven *Bacillus subtilis* *mrp* Genes Suggest Complex Interactions among the Gene Products in Support of Na<sup>+</sup> and Alkali but Not Cholate Resistance

MASAHIRO ITO,<sup>1</sup> ARTHUR A. GUFFANTI,<sup>2</sup> WEI WANG,<sup>2</sup> AND TERRY A. KRULWICH<sup>2\*</sup>

Faculty of Life Sciences, Toyo University, Oura-gun, Gunma 374-0193, Japan,<sup>1</sup> and Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, New York 10029<sup>2</sup>

Received 14 June 2000/Accepted 25 July 2000

The *Bacillus subtilis* *mrp* (multiple resistance and pH) operon supports Na<sup>+</sup> and alkali resistance via an Na<sup>+</sup>/H<sup>+</sup> antiport, as well as cholate efflux and resistance. Among the individual mutants with nonpolar mutations in each of the seven *mrp* genes, only the *mrpF* mutant exhibited cholate sensitivity and a cholate efflux defect that were complemented by expression of the deleted gene *in trans*. Expression of *mrpF* in the *mrp* null (VKN1) strain also restored cholate transport and increased Na<sup>+</sup> efflux, indicating that MrpF does not require even low levels of other *mrp* gene expression for its own function. In contrast to MrpF, MrpA function had earlier seemed to depend upon at least modest expression of other *mrp* genes, i.e., *mrpA* restored Na<sup>+</sup> resistance and efflux to strain VK6 (a polar *mrpA* mutant which expresses low levels of *mrpB* to *-G*) but not to the null strain VKN1. In a wild-type background, each nonpolar mutation in individual *mrp* genes caused profound Na<sup>+</sup> sensitivity at both pH 7.0 and 8.3. The *mrpA* and *mrpD* mutants were particularly sensitive to alkaline pH even without added Na<sup>+</sup>. While transport assays in membrane vesicles from selected strains indicated that MrpA-dependent antiport can occur by a secondary, proton motive force-dependent mechanism, the requirement for multiple *mrp* gene products suggests that there are features of energization, function, or stabilization that differ from typical secondary membrane transporters. Northern analyses indicated regulatory relationships among *mrp* genes as well. All the *mrp* mutants, especially the *mrpA*, *-B*, *-D*, *-E*, and *-G* mutants, had elevated levels of *mrp* RNA relative to the wild type. Expression of an upstream gene, *maeN*, that encodes an Na<sup>+</sup>/malate symporter, was coordinately regulated with *mrp*, although it is not part of the operon.

The *mrp* operon was first identified in the genome of *Bacillus subtilis* as a homologue of a locus that had been found to be centrally important to cytoplasmic pH regulation in alkaliphilic *Bacillus halodurans* C-125 (3, 16). A point mutation in the first gene of the alkaliphile homologue resulted in loss of Na<sup>+</sup>/H<sup>+</sup> antiporter activity (3). Such antiport is widely used by prokaryotes for alkali and Na<sup>+</sup> resistance inasmuch as coupled Na<sup>+</sup> exclusion and H<sup>+</sup> accumulation can be accomplished via electrogenic exchange of cytoplasmic Na<sup>+</sup> for a greater number of H<sup>+</sup> (14, 20). The complete *mrp* operon of *B. subtilis* is predicted to encode seven hydrophobic gene products (9, 12), as is also posited for homologues from diverse organisms, including alkaliphilic *Bacillus pseudofirmus* OF4 (14, 15), *Rhizobium meliloti* (21), *Staphylococcus aureus* (6), and others annotated in genome databases. Apart from the apparent role of the alkaliphile *mrp* operons in Na<sup>+</sup>-dependent pH homeostasis, studies with mutants have suggested that the *R. meliloti* homologue, *pha*, may encode a K<sup>+</sup>/H<sup>+</sup> antiporter that is required for symbiotic nitrogen fixation (21) and that *B. subtilis* *mrp* (called *ntr* and *sha* by other investigators [12, 13]) has multiple functions. First, the *B. subtilis* *mrp* locus has been shown to play a role in Na<sup>+</sup> resistance and in both Na<sup>+</sup>- and K<sup>+</sup>-dependent cytoplasmic pH homeostasis (9, 12). This is consistent with one or more *mrp* genes encoding an Na<sup>+</sup>(K<sup>+</sup>)/H<sup>+</sup> antiport activity. Recently, Kosono et al. (13) showed that

a *B. subtilis* *mrpA* (*shaA*) mutant fails to sporulate normally and suggested that an early step in sporulation is sensitive to the elevated cytoplasmic Na<sup>+</sup> concentration that results from *mrp* mutations. The second *B. subtilis* *mrp* activity, in which the *mrpF* gene has been implicated, encompasses cholate and Na<sup>+</sup> efflux activities, which may be mechanistically coupled. Demonstration of cholate efflux activity has thus far been made only in a mutant with a disruption in *mrpF* that also lowered expression of *mrpG* (9), but in the current study, separate mutations in *mrpF* and *mrpG* have been examined.

Before the discovery of the *mrp* operon and its homologues, the well-studied examples of Na<sup>+</sup>/H<sup>+</sup> antiporters all involved a single structural gene product (20). Data to date suggest that monovalent cation/H<sup>+</sup> antiporter activity requires the first gene of the operon, *mrpA*, in *B. subtilis*, but that other genes of the operon are required for some combination of antiporter activity, expression, and assembly (9, 12). That is, MrpA is necessary but not sufficient for Na<sup>+</sup>/H<sup>+</sup> activity. Similarly, Hiramatsu et al. (6) have suggested from studies in which the *S. aureus* homologue, designated *mmh*, was expressed in an Na<sup>+</sup>-sensitive *Escherichia coli* mutant, that all the genes of the operon may be required for the Na<sup>+</sup> resistance conferred in that system. There are recent reports of secondary multidrug transporters with two heterologous protein components (10, 18) but the complexity of the *mrp* product interactions might be of a much higher order. In addition, the long-recognized sequence similarity of several *mrp* products to membrane-embedded subunits of energy-coupled NADH dehydrogenase complexes (3, 9) raises the possibility that there is a capacity

\* Corresponding author. Mailing address: Box 1020, Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029. Phone: (212) 241-7280. Fax: (212) 996-7214. E-mail: terry.krulwich@msm.edu.

TABLE 1. Bacterial strains and plasmids used

Strain or plasmid	Relevant characteristic(s)	Source or reference
<i>E. coli</i> DH5 $\alpha$ MCR	F <sup>-</sup> <i>mcrA</i> $\Delta$ 1 ( <i>mrr-hsd RMS-mcrBC</i> ) $\Phi$ 80 <i>dlacZ</i> $\Delta$ ( <i>lacZYA-argF</i> )U169 <i>deoR recA1 endA1 supE44</i> $\lambda$ <i>thi-1</i> <i>gyr-496 relA1</i>	Gibco-BRL
<i>B. subtilis</i>		
BD99 (wild type)	<i>hisA1 thrS trpC2</i>	A. Garro
VK1A	BD99 $\Delta$ <i>mrpA</i>	9
VK1B	BD99 $\Delta$ <i>mrpB</i>	This study
VK1C	BD99 $\Delta$ <i>mrpC</i>	This study
VK1D	BD99 $\Delta$ <i>mrpD</i> ::Sp <sup>r</sup>	This study
VK1E	BD99 $\Delta$ <i>mrpE</i>	This study
VK1F	BD99 $\Delta$ <i>mrpF</i> ::Sp <sup>r</sup>	This study
VK1G	BD99 $\Delta$ <i>mrpG</i> ::Sp <sup>r</sup>	This study
VKN1	BD99 $\Delta$ <i>mrpA-G</i> ::Sp <sup>r</sup>	9
VK6	BD99 <i>mrpA</i> ::Sp <sup>r</sup>	This study
Plasmids		
pGEM11Zf(+)	Cloning vector (Ap <sup>r</sup> )	Promega
pDH88	Cm <sup>r</sup> vector for cloning <i>B. subtilis</i> chromosomal DNA and integration into the corresponding locus	5
pDR67	<i>amyE</i> integration vector with Cm <sup>r</sup> gene and <i>p</i> <sub>spac</sub> promoter upstream of multiple cloning site	8
pDHB1	pDH88 + $\Delta$ <i>mrpB</i>	This study
pDHC1	pDH88 + $\Delta$ <i>mrpC</i>	This study
pDHE1	pDH88 + $\Delta$ <i>mrpE</i>	This study
pDRB1	pDR67 + <i>mrpB</i>	This study
pDRC1	pDR67 + <i>mrpC</i>	This study
pDRD1	pDR67 + <i>mrpD</i>	This study
pDRE1	pDR67 + <i>mrpE</i>	This study
pDRF1	pDR67 + <i>mrpF</i>	This study
pDRG1	pDR67 + <i>mrpG</i>	This study
pGEMD1	pGEM11Zf(+)+ $\Delta$ <i>mrpD</i> ::Sp <sup>r</sup>	This study
pGEMF1	pGEM11Zf(+)+ $\Delta$ <i>mrpF</i> ::Sp <sup>r</sup>	This study
pGEMG1	pGEM11Zf(+)+ $\Delta$ <i>mrpG</i> ::Sp <sup>r</sup>	This study

for electron transport that could provide a primary energy coupling option for *mrp* functions.

In the current study, individual in-frame deletions were made in each of the *B. subtilis mrp* genes for which no such mutations had been made earlier, i.e., *mrpB*, *-C*, *-D*, *-E*, *-F*, and *-G*. For each of those strains, a version was also made in which an active copy of the disrupted gene was returned to the *amyE* locus of the chromosome under the control of an IPTG (isopropyl- $\beta$ -D-thiogalactopyranoside)-inducible promoter. Each *mrp* gene was similarly introduced into the *amyE* locus of an *mrp* null mutant, VKN1, of *B. subtilis*, and into that of a polar mutant, VK6, that lacks *mrpA* and expresses *mrpB* to *-G* at greatly reduced levels. Resistance and transport studies have supported earlier indications that MrpF is the Na<sup>+</sup>-chololate efflux protein and further show that MrpF activity is independent of the expression of additional *mrp* genes. By contrast, MrpA function, which is shown to correlate with a protonophore-sensitive Na<sup>+</sup> efflux activity, requires all six other *mrp* genes. In addition, evidence is presented for a complex regulatory relationship between loss of function of particular *mrp* genes and expression of the polycistronic *mrp* mRNA.

#### MATERIALS AND METHODS

**Bacterial strains, plasmids, and general growth conditions.** The bacterial strains and plasmids used in this study are listed in Table 1. The bacteria were routinely grown at 30°C in malate-containing, potassium-replete TKM medium (9). For experiments in which *mrp* genes were introduced into the *amyE* locus under control of the *p*<sub>spac</sub> promoter, 200  $\mu$ M IPTG was included in the growth medium.

**Northern analyses.** Cells were grown, RNA was prepared, and the Northern procedures were carried out according to methods described by others (2). Three

different probes were employed: (i) a probe to a gene upstream of the *mrp* operon that encodes *maeN* (*yufR*) was prepared using primers *yufR1* and *yufR2*; (ii) a probe to part of *mrpA* was prepared using primers BsmrpA1 and *mrpA2T7*; and (iii) a probe to part of *mrpG* was prepared using primers BsmrpG1 and *mrpG2T7*. For these preparations as well as other PCRs, either Pfx (Life Tech) or Vent (New England Biolabs) DNA polymerase was used. The PCR products were first gel purified and then eluted using a gel extraction kit (Qiagen). The probes were then used as DNA templates for random priming <sup>32</sup>P labeling using a random-primed DNA labeling kit (Roche Diagnostics). The locations of the probes are indicated in Fig. 1.

**Construction of mutant strains.** For each type of mutant, the phenotype of the strain used in the studies was the same as that of several other strains from the construction protocol. Each mutant that was used in the subsequent studies was initially confirmed to have the expected PCR profile and was then directly shown to contain the expected sequence. Sequencing was conducted at the Biotechnology Center at Utah State University (Logan, Utah) with an ABI-100 model 377 sequencer. All in-frame mutations were constructed by gene splicing via overlap extension, as described by others (7). For the deletions of *mrpB*, *mrpC*, and *mrpE*, the approach was precisely as used in earlier construction of the VK1A (*mrpA* deletion, previously called VK1) strain (9). For deletions in *mrpD*, *mrpF*, and *mrpG*, the earlier approach alone did not yield the desired mutations; therefore, gene splicing via overlap extension was used as the first step, followed by steps that resulted in the introduction of a spectinomycin resistance (Sp<sup>r</sup>) cassette gene, *spc* (19), into the deleted area.

(i) For construction of in-frame mutant VK1B with a deletion in *mrpB*, two independent PCRs were performed on wild-type DNA with the sets of primers shown in Fig. 1, BF-X1 and B-MR plus BR-B2 and B-MF. The sequences of the primers used in this study will be made available from the authors. BF-X1 has additional nucleotides encoding an *XbaI* site. BR-B2 has additional nucleotides encoding a *BglII* site. The two purified PCR products were used as templates for a second PCR with primers BF-X1 and BR-B2. The purified product of this reaction was digested with *XbaI* and *BglII* and then cloned into *XbaI*- and *BglII*-digested pDH88. The resulting plasmid, pDHB1, was integrated into the *mrpB* locus in the chromosome by a single crossover using chloramphenicol resistance for selection (5). To prepare strains that had lost the plasmid sequences, leaving a mutated *mrpB*, cells were grown under nonselective conditions on LBK plates, and the strains thus obtained were confirmed as above.

(ii) For construction of in-frame mutant VK1C with a deletion in *mrpC*, the strategy (Fig. 1) was the same as for VK1B except that the primer pairs were CF-X1 and C-MR plus CR-B2 and C-MF. The two purified PCR products were used as templates for a second PCR using primers CF-X1 and CR-B2. The product of this reaction was cloned into pDH88 as above, resulting in plasmid pDHC1, which was integrated into the *mrpC* locus. Strains that had lost the plasmid sequences were isolated and confirmed.

(iii) For construction of in-frame mutant VK1D with a deletion in *mrpD*, two PCRs were performed on wild-type DNA with primer pairs CF-X1 and D-MRS1 plus MRFPB2 and D-MFS1 (Fig. 1). MRFPB2 has additional nucleotides encoding a *BglII* site. D-MRS1 and D-MFS1 have additional nucleotides encoding a *SmaI* site in the middle of each primer. The two purified PCR products were used as templates for a second PCR with primers CF-X1 and MRFPB2. The purified product of this reaction was digested with *XbaI* and *BglII* and then cloned into *XbaI*- and *BamHI*-digested pGEM11Zf(+). (Ap<sup>r</sup>; Promega). The recombinant plasmid was digested with *SmaI*. Just before the *SmaI* site, the third amino acid from the N terminus of MrpD is encoded, and just after the *SmaI* site, the third amino acid from the C terminus of MrpD is encoded. A gene encoding Sp<sup>r</sup> was amplified by PCR using primers SpcA and SpcB. The PCR product encoded only the open reading frame region of the *spc* gene. The *spc* gene was ligated to this linear plasmid in frame, resulting in a recombinant plasmid encoding a chimeric protein containing a small part of MrpD and the Spc<sup>r</sup> protein. This chimeric protein conferred spectinomycin resistance. After isolation, the recombinant plasmid, pGEMD1, was digested with *XbaI*, and the linear plasmid was introduced into wild-type *B. subtilis*. Mutants with deletions in *mrpD* were identified by spectinomycin resistance (150  $\mu$ g/ml) and confirmed.

(iv) For construction of in-frame mutant VK1E with a deletion in *mrpE*, the strategy was the same as for VK1B (Fig. 1) except that the primer pairs were EF-X1 and E-MR plus ER-B2 and E-MF. The two purified PCR products were used as templates for a second PCR with primers EF-X1 and ER-B2. The purified PCR product was cloned into pDH88, resulting in plasmid pDHE1, which was integrated into the *mrpE* locus. Clones that had lost the plasmid sequence were isolated and confirmed.

(v) For construction of in-frame mutant VK1F with a deletion in *mrpF*, two PCR were performed on wild-type DNA with the sets of primers shown in Fig. 1, FF-X1 and F-MRS1 plus FR-B1 and F-MFS1 (Table 2). FF-X1 has additional nucleotides encoding an *XbaI* site. FR-B1 has additional nucleotides encoding a *BamHI* site. F-MRS1 and F-MFS1 have additional nucleotides encoding a *SmaI* site in the middle of each primer. The two purified PCR products were used as templates for a second PCR with primers FF-X1 and FR-B1. The purified product of this reaction was digested with *XbaI* and *BamHI* and then cloned into *XbaI*- and *BamHI*-digested pGEM11Zf(+). The recombinant plasmid was digested with *SmaI*. Just before the *SmaI* site, the first amino acid from the N terminus of MrpF is encoded, and just after the *SmaI* site, the sixth amino acid from the C terminus of MrpF is encoded. A recombinant plasmid, pGEMF1,




FIG. 1. Schematic diagram of the *yufR* (*maeN*)-*mrp* region of the *B. subtilis* chromosome that indicates the probes used for Northern analyses and the primers used in construction of new *mrp* deletion strains.

containing a very short part of *mrpF* and an *Sp<sup>r</sup>* gene was constructed as for VK1D. The plasmid was introduced into *B. subtilis*, and deletion of *mrpF* was confirmed.

(vi) For construction of in-frame mutant VK1G with a deletion in *mrpG*, the strategy was as for VK1F. Two independent PCRs were performed on wild-type DNA using primer pairs GF-X1 and G-MRS1 plus FR-B1 and G-MFS1. GF-X1 has additional nucleotides encoding an *Xba*I site; FR-B1 has a *Bam*HI site; and G-MRS1 and G-MFS1 have a *Sma*I site in the middle of each primer. The two purified PCR products were used as templates for a second PCR with primers GF-X1 and FR-B1. The PCR product was cloned into pGEM11Zf(+) as for VK1F. The recombinant plasmid was digested with *Sma*I. Just before the *Sma*I site, the sixth amino acid from the N terminus of MrpG is encoded, and just after the *Sma*I site, the stop codon of MrpG is encoded. A recombinant plasmid containing a small part of *mrpG* and a spectinomycin resistance gene was introduced into *B. subtilis*, and deletion of *mrpG* was confirmed.

Integration of various *mrp* genes into the *amyE* locus of particular mutant strains was performed as described elsewhere using plasmid pDR67 (8). For construction of a plasmid carrying the intact *mrpB* gene, PCR was performed on wild-type DNA using primers MRPBX1 and MRPBB2 (Fig. 1). For *mrpC*, the primers were MRPCX1 and MRPCB2. For *mrpD*, the primers were MRPDX1 and MRPDB2. For *mrpE*, the primers were MRPEX1 and MRPEB2. For *mrpF*, the primers were MRPFX1 and MRPFB2. For *mrpG*, the primers were MRPGX1 and ER-B2. Each amplified fragment was cloned into *Xba*I- and *Bgl*III-digested pDR67, yielding pDRB1, pDRC1, pDRD1, pDRF1, and pDRG1, respectively. Each plasmid was linearized with *Nru*I and used to transform particular mutants to a chloramphenicol-resistant, amylase-negative phenotype. The plasmids used in this study are listed together with the bacterial strains in Table 1. All were confirmed to have the correct sequences.

**Determination of MICs of Na<sup>+</sup> and inhibition profile for cholate.** The MIC of Na<sup>+</sup> was determined in TKM medium at pH 7.0 or 8.3 exactly as described elsewhere (9). Sensitivity to cholate was also assessed as previously described (9).

**Transport assays.** Measurements of cholate efflux were conducted on whole cells that were preloaded with cholate and then assayed using a filtration assay as described in connection with earlier studies of the *mrp* operon (9). Measurements of <sup>22</sup>Na<sup>+</sup> efflux were conducted in both whole cells and right-side-out membrane vesicles. The whole-cell <sup>22</sup>Na<sup>+</sup> efflux assays conducted in connection

with MrpF function were carried out precisely as described earlier (9). For the assays in membrane vesicles, right-side-out vesicles were prepared by a modification of the method of Kaback (11). Protoplasts were prepared from logarithmic-phase cells by incubating at 37°C in 100 mM potassium phosphate (pH

TABLE 2. Na<sup>+</sup> resistance of *B. subtilis* strains with mutations in selected *mrp* genes

Strain	MIC <sup>a</sup> (M) of Na <sup>+</sup> at:			
	pH 7.0		pH 8.3	
	Na <sup>+</sup> concn (M)	A <sub>600</sub>	Na <sup>+</sup> concn (M)	A <sub>600</sub>
Wild type	1.30 ± 0.05	0.996	0.71 ± 0.03	0.646
VKN1	0.09 ± 0.03	0.984	0.024 ± 0.006	0.694
VK1A	0.15 ± 0.02	0.912	0.03 ± 0.004	0.301
VK1B	0.12 ± 0.02	0.946	0.025 ± 0.005	0.763
VK1C	0.21 ± 0.02	0.896	0.057 ± 0.005	0.733
VK1D	0.22 ± 0.01	0.832	0.015 ± 0.004	0.141
VK1E	0.11 ± 0.02	0.951	0.023 ± 0.005	0.637
VK1F	0.19 ± 0.02	0.836	0.052 ± 0.007	0.684
VK1G	0.22 ± 0.02	0.864	0.073 ± 0.008	0.648
VK1A ( <i>mrpA</i> )	1.15 ± 0.05	0.991	0.45 ± 0.02	0.598
VK1B ( <i>mrpB</i> )	1.11 ± 0.03	0.947	0.51 ± 0.02	0.604
VK1C ( <i>mrpC</i> )	1.30 ± 0.04	0.925	0.73 ± 0.04	0.675
VK1D ( <i>mrpD</i> )	0.90 ± 0.03	0.954	0.47 ± 0.03	0.497
VK1E ( <i>mrpE</i> )	1.32 ± 0.04	0.961	0.62 ± 0.04	0.668
VK1F ( <i>mrpF</i> )	1.35 ± 0.05	0.924	0.72 ± 0.04	0.675
VK1G ( <i>mrpG</i> )	1.22 ± 0.04	0.978	0.71 ± 0.03	0.661

<sup>a</sup> Minimal Na<sup>+</sup> concentration at which no growth was observed after 15 h. The values are means of at least eight separate determinations ± standard deviations. A<sub>600</sub> values are after 15 h.






FIG. 2. Northern analyses of mutants with individual deletions in each of the seven *B. subtilis* *mrp* genes. RNA was prepared from wild-type *B. subtilis* and probed with the DNA probes corresponding to parts of the first and last *mrp* genes and to part of the upstream *maeN* (*yufR*) gene. The locations of the probes are shown in Fig. 1, and the procedures are described in Materials and Methods. The strain is indicated above each lane, e.g., Wt, wild type; A, VK1A; etc. The probe used for the particular blot is indicated below the panel.

7.5)–20% sucrose–300  $\mu$ g of lysozyme per ml until the cells had rounded up. The protoplasts were shocked in 50 mM potassium phosphate (pH 7.5) plus 1 mM  $MgSO_4$  by diluting 100-fold and passing through a syringe with a 19G1/2 needle. Vesicles were passively loaded with 5 mM  $^{22}NaCl$  (10  $\mu$ Ci/ml) for 18 h at 4°C. For assays of  $Na^+$  efflux energized by the electron transport chain, vesicles (100  $\mu$ g of protein/ml) were incubated at 10°C. No further additions were made, or 10 mM potassium ascorbate–0.1 mM phenazine methosulfate (PMS) was added. The protonophore carbonyl cyanide *p*-chlorophenylhydrazone (CCCP) was added to some reactions, as indicated. Samples were taken at various times and filtered, and radioactivity was measured by liquid scintillation counting.

In some assays  $Na^+$  efflux was driven by a potassium diffusion potential. The membrane vesicles loaded with 5 mM  $^{22}Na^+$  in buffer containing 100 mM potassium phosphate (pH 7.5) were treated with 10  $\mu$ M valinomycin and diluted to various extents into 50 mM Tris-HCl (pH 7.5) in order to generate potassium diffusion potentials of different magnitudes. Samples were taken at 5 s after dilution, and radioactivity was counted as above. Protein was determined by the method of Lowry et al. (17), using egg white lysozyme as the standard.

## RESULTS

**Northern analyses of the mutant strains.** Northern analyses were conducted on each of the newly constructed strains, the VK1A strain constructed earlier (9), and the wild type. Three different probes were used. One was to the upstream *maeN* (*yufR*) gene, which has been shown to encode a  $Na^+$ /malate symporter (Y. Wei, unpublished data). This gene is transcribed in the same direction as the *mrp* genes, and the possibility that it is cotranscribed or coregulated with them was of interest. The other two probes were to the *mrp* genes at the ends of the known operon, *mrpA* and *mrpG*. These probes were used to determine whether the new in-frame deletion mutations were in fact nonpolar, and whether all of the new mutants exhibited increased *mrp* RNA abundance. The *mrpA* deletion in strain VK1A had earlier been shown to be nonpolar and to result in much higher levels of *mrp* RNA than the wild type (9). As shown in Fig. 2, all the new inframe deletion mutations (*mrpBCDEF*) are nonpolar inasmuch as the cells express *mrpG* at wild-type levels of RNA abundance or greater. In Fig. 2, an arrow indicates the location of the wild-type *mrp* band. This band could only be visualized more distinctly upon longer exposures, which made it too difficult to discern any detail in most of the other lanes. The sizes of the *mrp* bands in the mutants were as expected from the size of the deletion combined, in three of them, with the introduction of a cassette. As had been observed for *mrp* RNA in VK1A (9) (which is shown again in Fig. 2 together with the new mutants), the new mutants with deletions in *mrpB*, *mrpE*, *mrpD*, and *mrpG* all exhibited a significant increase in *mrp* RNA, as did the retested *mrpA* mutant. Two of the new mutants with deletions in *mrpC* or *mrpF* did not exhibit an elevation of *mrp* RNA comparable to that seen in the other strains, although there was still an increase relative to the wild-type strain. In the RNA preparations from some of the mutants, there were also bands that reacted with *mrp* gene probes that were smaller than the major, expected band and may represent degradation products.

A distinct band corresponding to the molecular size of *maeN* alone was observed with the *maeN* probe. This indicates

that *maeN* is expressed on a transcript that probably encodes no other genes and is not included on the large *mrp* transcript under the conditions used here. Interestingly, the level of *maeN* RNA, which was higher in the wild type than the level of *mrp* RNA, exhibited a pattern of increase among the *mrp* mutants that was similar to that for *mrp* RNA. *maeN* RNA was elevated over its wild-type level in all the *mrp* mutants except the *mrpA* mutant. That mutant, VK1A, showed less *maeN* RNA than the wild type. Among the other *mrp* mutants, there again appeared to be a smaller increase in the strains with deletions in *mrpC* or *mrpF* relative to the other, *maeN*-over-expressing mutants.

**MrpF-dependent cholate resistance, cholate efflux, and  $Na^+$  efflux.** Cholate resistance was examined in our initial studies of the *B. subtilis* *mrp* operon because the BLAST analysis (1) of the deduced *mrpF* product revealed sequence similarities to  $Na^+$ -coupled bile acid transporters. The difference in cholate resistance found between the wild type and *mrpF* (polar) mutant, VK15, was significant and reproducible but not large enough to be captured as a difference in MIC (9). As shown in Fig. 3 for each of the single *mrp* gene mutants and their complemented versions, a large increase in sensitivity to cholate was found only in the new *mrpF* (nonpolar) mutant VK1F, and only in that mutant was the restoration of an active gene in the *amyE* locus accompanied by significantly greater resistance to cholate. To correlate the resistance with cholate transport capacity, the efflux of cholate from preloaded cells of the wild type was compared to efflux from the *mrpF* and *mrpG* mutants, VK1F and VK1G, respectively, and the versions of each in which the affected gene was expressed from the *amyE* locus. As shown in Fig. 4A, efflux of cholate was not defective in the *mrpG* mutant strain but was significantly reduced in the *mrpF* mutant strain VK1F. Expression *in trans* of the *mrpF* gene in VK1F increased the cholate efflux activity of the mutant almost to the level in VK1G (Fig. 4A) or the wild-type strain (Fig. 4B). Earlier studies indicated that expression of *mrpF* in the *mrp* null strain of *B. subtilis* did not restore cholate resistance to that strain (9). However, the results here led us to reexamine the possibility that MrpF can function independently of any other *mrp* genes in experiments in which transport of cholate itself was assayed. Efflux and resistance might not be observed in parallel, for example, if cholate reentry was pronounced relative to the capacity and rate of efflux. As shown in Fig. 4B, expression of *mrpF* under control of an IPTG-inducible promoter in the *amyE* locus of *mrp* null strain VKN1 resulted in a dramatic increase in cholate efflux. Expression of *mrpF* in strain VKN1 also resulted in an increase in  $Na^+$  efflux (Fig. 5), although, as noted below, this increase too was not sufficient to be reflected in an increase in  $Na^+$  resistance.

**$Na^+$  and alkali- sensitivity of the *mrp* mutants.** The MIC of  $Na^+$  was determined in the wild type (BD99), in the *mrp* null strain (VKN1), in each of the single *mrp* gene deletion strains, and in each of the deletion strains with the gene restored in the




FIG. 3. Sensitivity of wild type (wt) and *mrp* mutant strains of *B. subtilis* to growth inhibition by cholate. Cells were grown in TKM medium (pH 7.0) in the presence (hatched bars) or absence (open bars) of 0.08% (wt/vol) cholate. After 6 h of incubation with shaking at 30°C, the  $A_{600}$  was determined. The results represent the mean of at least eight determinations, and standard deviations are shown as error bars.

*amyE* locus. The determinations were made at pH 7.0 and at pH 8.3 as described in Materials and Methods. The two pHs were examined because of the role of the  $\text{Na}^+/\text{H}^+$  antiport in both  $\text{Na}^+$  and alkali resistance and because  $\text{Na}^+$  cytotoxicity is elevated at alkaline pH (14, 20). A record was kept of the  $A_{600}$  after 15 h of growth in the absence of added  $\text{Na}^+$  at each pH (i.e., the same time at which growth was recorded for  $\text{Na}^+$ -

containing cultures) as an indicator of cell yield of each mutant at the two pHs. As shown in Table 2, all of the *mrp* mutants were from 6 to >10 times more sensitive to  $\text{Na}^+$  than the wild-type strain at pH 7.0, and there were no major differences in the absorbances reached by the different mutants and the wild type in the absence of added  $\text{Na}^+$ . Restoration of the mutated gene to each of the single deletion mutants resulted in




FIG. 4. Cholate efflux from whole cells of wild-type and selected *mrp* mutant strains of *B. subtilis*. The cells were starved and loaded with  $20 \mu\text{M}$  [ $^{14}\text{C}$ ]cholate. Efflux was initiated by diluting 100-fold into buffer containing 10 mM glucose. Samples were taken at various times, filtered, and washed. The radioactivity was determined by liquid scintillation counting. (A) *mrpF* mutant VK1F and *mrpG* mutant VK1G, both without (solid symbols) and with (open symbols) the deleted gene expressed from an IPTG-inducible promoter in the *amyE* locus. (B) Wild-type strain, the *mrp* null mutant VKN1, and VKN1 expressing *mrpF* under control of an IPTG-inducible promoter in the *amyE* locus.




FIG. 5.  $^{22}\text{Na}^+$  efflux from wild-type (wt) *B. subtilis*, the *mrp* null strain VKN1, and VKN1 expressing *mrpF* in *trans*. The cells were washed, energy depleted, and loaded with 5 mM  $^{22}\text{NaCl}$  as described previously (9). Efflux was initiated by diluting the cell suspension 100-fold into buffer containing 5 mM NaCl with no further additions (○) or in the presence of 10 mM glucose (●). Samples were taken at various times, filtered, and washed. The radioactivity was determined by liquid scintillation counting.

complementation in *trans* that resulted in essentially wild-type MICs for each of the mutants. At pH 8.3, the patterns were more complex. First, the *mrpA* and *mrpD* mutants, VK1A and VK1D, respectively, exhibited poor growth at the elevated pH in the absence of added  $\text{Na}^+$ . This deficit was especially pronounced with VK1D, in which reintroduction of the gene in the *amyE* locus did not completely restore wild-type levels of growth. Second, all of the mutants exhibited at least 10-fold-greater sensitivity to  $\text{Na}^+$  than the wild type at pH 8.3, but the sensitivity of the *mrpA*, *mrpB*, *mrpD*, and *mrpE* mutants (VK1A, VK1B, VK1D, and VK1E, respectively) was reproducibly greater than that of the other three strains, with VK1D being the most  $\text{Na}^+$  sensitive of all the mutants. The most sensitive strains were also those that were not completely complemented up to wild-type levels upon restoration of the affected gene in *trans*.

**Effects of expression of individual *mrp* genes in *trans* on the  $\text{Na}^+$  resistance of VK6 and VKN1 mutant strains.** Unlike cholera resistance, which depended upon the status of a single *mrp* gene, wild-type levels of  $\text{Na}^+$  resistance clearly depended upon the status of multiple *mrp* genes. Previous work had shown that expression of *mrpA* from an IPTG-inducible promoter in the *amyE* locus of mutant strain VK6 led to a significant increase in the  $\text{Na}^+$  resistance as well as the  $^{22}\text{Na}^+$  efflux activity of that strain. VK6 has a disrupted *mrpA* and reduced expression of *mrpB* through *-G* (9). No such increase in either resistance or efflux was observed upon expression of *mrpA* in the *mrp* null strain VKN1. We sought to assess whether MrpA is the likeliest candidate for the  $\text{Na}^+$ -translocating protein in Mrp-dependent  $\text{Na}^+/\text{H}^+$  antiport, albeit dependent in some manner on all the other *mrp* gene products as well. Each *mrp* gene was individually expressed in VK6 (VK6/*mrpA* through VK6/*mrpG*) and VKN1, and the MIC of  $\text{Na}^+$  was determined pH 7.0 and 8.3. As expected from earlier assays (9), expression of *mrpA* and *mrpF* increased the resistance of strain VK6 to  $\text{Na}^+$ . Only *mrpB* expression among all the remaining *mrp* genes caused a significant increase in resistance and that was restricted to pH 7.0 (Table 3). In the *mrp* null strain VKN1, no single *mrp* gene caused a significant, reproducible increase in  $\text{Na}^+$  resistance (data not shown).

**Energy-dependent efflux of  $^{22}\text{Na}^+$  from right-side-out membrane vesicles of *B. subtilis* wild-type and selected *mrp* mutant strains.** Prior studies of *mrp*-dependent  $\text{Na}^+$  fluxes had been conducted on respiring whole cells, in which significant cyanide- and protonophore-dependent inhibition was observed,

especially for efflux from cells of mutant VK1A, in which *mrpA* expression was induced in *trans* (9). Reproducible data showing that an imposed diffusion potential could also energize such efflux had not been obtained in the whole-cell system. In order to further explore an MrpA-dependent capacity for secondary  $\text{Na}^+/\text{H}^+$  antiport, right-side-out membrane vesicles of the wild-type and selected mutant strains were assayed for MrpA- and energy-dependent  $^{22}\text{Na}^+$  efflux. Ascorbate-PMS was found to support significant enhancement of the rate of  $^{22}\text{Na}^+$  efflux from vesicles prepared from the wild type and from VK1A/*mrpA* but only slight enhancement of efflux from the control preparations from the null VKN1 or VK1A strains (Fig. 6). The protonophore CCCP abolished the ascorbate-PMS-dependent efflux. The four preparations were then examined at a range of imposed valinomycin-mediated  $\text{K}^+$  diffusion potentials, with points taken during the initial efflux period under each condition. The percent  $^{22}\text{Na}^+$  remaining at 5 s is plotted in Fig. 7 for each preparation as a function of the magnitude of the imposed diffusion potential. The difference among the preparations correlated well, especially at the lowest diffusion potential established,  $-60$  mV, with the ascorbate-PMS-dependent pattern. That is,  $\text{Na}^+$  efflux from the wild type and VK1A/*mrpA* was significantly greater than that from VKN1 or VK1A. At higher imposed potentials, efflux via some other transporter may be a more dominant contributor to the observed pattern.

TABLE 3.  $\text{Na}^+$  resistance of the polar *mrpA* mutant of *B. subtilis* strain VK6 upon expression of individual *mrpA* genes

Strain	MIC <sup>a</sup> (M) of $\text{Na}^+$ at:	
	pH 7.0	pH 8.3
Wild type	1.30 ± 0.05	0.71 ± 0.03
VK6	0.29 ± 0.03	0.025 ± 0.01
VK6/ <i>mrpA</i>	0.62 ± 0.04	0.15 ± 0.02
VK6/ <i>mrpB</i>	0.36 ± 0.02	0.04 ± 0.01
VK6/ <i>mrpC</i>	0.19 ± 0.02	0.031 ± 0.01
VK6/ <i>mrpD</i>	0.18 ± 0.02	0.025 ± 0.01
VK6/ <i>mrpE</i>	0.23 ± 0.02	0.028 ± 0.01
VK6/ <i>mrpF</i>	0.46 ± 0.02	0.16 ± 0.01
VK6/ <i>mrpG</i>	0.22 ± 0.02	0.045 ± 0.01

<sup>a</sup> Minimal  $\text{Na}^+$  concentration at which no growth was observed after 15 h. The values are means of at least eight separate determinations ± standard deviations.




FIG. 6. Ascorbate-PMS-dependent  $^{22}\text{Na}^+$  efflux from right-side-out membrane vesicles of wild-type *B. subtilis* (BD99), *mrp* null mutant VKN1, *mrpA* mutant VK1A, and VK1A to which *mrpA* is restored in the *amyE* locus. The vesicles were passively loaded overnight at  $4^\circ\text{C}$  with 5 mM  $^{22}\text{NaCl}$  in 100 mM potassium phosphate (pH 7.5) plus 5 mM  $\text{MgSO}_4$ . For assays of  $\text{Na}^+$  efflux, vesicles (100  $\mu\text{g}$  of protein/ml) were incubated at  $10^\circ\text{C}$ . No further additions were made ( $\circ$ ), or 10 mM potassium ascorbate plus 0.1 mM PMS was added in the absence ( $\bullet$ ) or presence ( $\blacktriangle$ ) of 10  $\mu\text{M}$  CCCP. Samples were taken at various times and rapidly filtered. The radioactivity on the filters was measured by liquid scintillation counting.

## DISCUSSION

The *mrp* operon and its homologues are widely distributed among diverse prokaryotes and function in multiple processes involving ion-coupled transport reactions. Thus far, only one of these operons, the *mrp* operon of *B. subtilis*, has been shown to catalyze different transport reactions that relate to different gene products within the operon. The major finding of the current study is that MrpF can function in cholate and  $\text{Na}^+$  efflux independently of any other *mrp* gene product, whereas MrpA-dependent  $\text{Na}^+/\text{H}^+$  antiport activity and  $\text{Na}^+$  resistance are highly dependent upon other *mrp* gene products, probably requiring all six of them. MrpA is a strong candidate for a major, if not sole, structural gene for Mrp-encoded  $\text{Na}^+/\text{H}^+$  antiport, since the antiport activity of *mrpA* mutant VK1A, which has elevated levels of all the remaining *mrp* genes, has low  $\text{Na}^+$  resistance and efflux activities. In addition, *mrpA* overexpression in mutant VK6 (polar) elevates the  $\text{Na}^+$  resistance of that strain more than overexpression of any of the other *mrp* genes.

We tentatively hypothesize that the  $\text{Na}^+$  efflux catalyzed by MrpF is coupled to solute efflux (e.g., endogenous cholate-like substrate and/or exogenous cholate-like compounds) rather than being a true  $\text{Na}^+/\text{H}^+$  antiport mode of this independent transporter. However, the assays conducted to date of MrpF-dependent cholate and  $\text{Na}^+$  efflux have not shown that there actually is coupling between the two substrates. In the whole cells in which the assays have thus far been conducted, there are complications of high contaminating  $\text{Na}^+$  levels, multiple antiporters apart from *mrp*, and the potential presence of an endogenous substrate that could substitute for preloaded cholate. Attempts to assess coupling of cholate efflux by MrpF in vesicles from the current *B. subtilis* strains were not undertaken because of their substantial  $\text{Na}^+/\text{H}^+$  antiport activities as well as difficulties that we have had in making good everted vesicle preparations from these strains. Future studies will attempt to clarify the possible  $\text{Na}^+$ -cholate coupling in everted vesicles from appropriate *Escherichia coli* strains if, as is now anticipated, expression of MrpF alone yields an active transporter. Moreover, attempts will be made to identify a transport activity for additional *mrp* gene products, especially MrpB and MrpC.

The basis for the MrpB-dependent increase in the  $\text{Na}^+$  resistance of strain VK6 at pH 7.0 is of interest. The Block+ program for motif analysis (4) does not provide useful clues vis à vis a specific MrpB transport activity, but indicates that MrpC

has some similarities to  $\text{Na}^+$ -coupled organic acid transporters. If there were one or more additional contributors to overall Mrp-dependent  $\text{Na}^+$  efflux, that would explain why *mrpA* and *mrpF* mutants have slightly but reproducibly higher  $\text{Na}^+$  resistance than the *mrp* null strain VKN1 at pH 7.0. No attempt can be made to interpret the differences in MIC at pH 8.3, since the levels of  $\text{Na}^+$  that are toxic to the *mrp* mutants at




FIG. 7. Efflux of  $^{22}\text{Na}^+$  from right-side-out membrane vesicles of wild-type *B. subtilis* (BD99) and strains VKN1, VK1A, and VK1A/*mrpA* as a function of the magnitude of an imposed potassium diffusion potential. Membrane vesicles were loaded with  $^{22}\text{Na}^+$  as described in the legend to Fig. 6 in buffer containing 100 mM potassium phosphate and 10  $\mu\text{M}$  valinomycin. These vesicles were diluted to different extents into 50 mM Tris-HCl (pH 7.5), in order to generate diffusion potentials of different magnitudes (indicated on the bottom of the figure). Samples were taken at 5 s after dilution and rapidly filtered. The radioactivity was determined by scintillation counting.



that pH are already in the range of contaminating  $\text{Na}^+$ , and thus assessments of differences are unlikely to be accurate. The striking growth deficit of *mrpA* and *mrpD* mutants in the absence of added  $\text{Na}^+$  at pH 8.3 might in fact reflect a much greater  $\text{Na}^+$  sensitivity, effected by contaminating levels, in these strains. The evident importance of *mrpD* at high pH is intriguing, especially since its overexpression does not increase the  $\text{Na}^+$ -resistance of polar *mrpA* strain VK6, and thus it is unlikely to be an antiporter protein itself.

The studies of MrpA-dependent  $\text{Na}^+$  efflux in the right-side-out vesicles of VK1A/*mrpA* support the earlier indication from whole-cell assays (9) that the  $\text{Na}^+/\text{H}^+$  antiporter can function as a secondary, proton motive force-dependent antiporter. However, although not shown, we were unable to demonstrate efflux at pH 8.0 and 8.3 in these vesicles even though Mrp-dependent  $\text{Na}^+$  efflux in malate-utilizing cells is clearly an important function at this pH. The possibility of a primary coupling mode for Mrp-dependent  $\text{Na}^+/\text{H}^+$  antiport, using redox energy, is underscored by the importance and efficacy of the Mrp system in cells at elevated pH; by the complex dependence of the antiport on multiple *mrp* gene products; by the importance of MrpD at elevated pH; and by the strong sequence similarity between several *mrp* gene products—especially MrpA, MrpB, MrpE, and MrpD—to hydrophobic subunits of energy-coupled NADH dehydrogenase and to regions of other redox proteins (as analyzed via BLAST [1] and Block+ [4]). To explore possible primary energization, we are undertaking studies of the *Bacillus mrp* operons expressed in various *E. coli* strains. If a redox-dependent activity and complex formation are supported, it will be important to identify the electron donors and acceptors which would facilitate any subsequent efforts to study a purified Mrp complex.

Another final set of observations of interest in the current study emerge from the Northern analyses. Evidently, deletion of any of the *mrp* genes results in a significant increase in *mrp* expression, with the effect being somewhat smaller in *mrpC* and *mrpF* mutants. A simple interpretation would be that a rise in cytoplasmic  $\text{Na}^+$  leads to the overexpression. Even if correct, there are many features left to elucidate, including the basis for the difference between the effect in *mrpC* and *mrpF* mutant strains as well as the elements and mechanism of the putative regulatory effect. Another finding that will merit further exploration is that expression of *maeN*, which encodes an  $\text{Na}^+$ -malate symporter, is partially coordinated with expression of *mrp* except that its basal expression is much greater and lower rather than greater levels of *maeN* RNA are observed in the *mrpA* mutant VK1A. The greatly reduced levels of *maeN* RNA in the VK1A strain may reflect disruption of some feature in the regulatory interaction between *maeN* and *mrp* that is lost during construction of the *mrpA* deletion. The regulatory coupling of *maeN* and *mrp* suggests the importance under at least some growth conditions of coordinating a full  $\text{Na}^+$  cycle. Such a cycle would encompass  $\text{Na}^+/\text{malate}$  symport and  $\text{Na}^+$  reextrusion in exchange for  $\text{H}^+$  and also coupled to (MrpF-dependent) efflux of external chaotropes (e.g., cholate) and perhaps additional metabolic by-products. Under alkaline pH conditions, such an  $\text{Na}^+$ -coupled cycle could be particularly important for achieving both substrate uptake and cytoplasmic

pH regulation, and its efficacy would be enhanced if a primary, redox-coupled energization option existed for one or more of the efflux activities.

#### ACKNOWLEDGMENTS

This work was supported in part by research grants DE-FG02-86ER13559 from the Department of Energy and GM28454 from the National Institute of General Medical Sciences to T.A.K. and from the Inoue Enryo Memorial Foundation for Promoting Science to M.I.

#### REFERENCES

- Altschul, S. F., W. Gish, W. Miller, E. F. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. *J. Mol. Biol.* **215**:403–410.
- Dimari, J. F., and D. Bechhofer. 1991. Initiation of mRNA decay in *Bacillus subtilis*. *Mol. Microbiol.* **7**:705–717.
- Hamamoto, T., M. Hashimoto, M. Hino, M. Kitada, Y. Seto, T. Kudo, and K. Horikoshi. 1994. Characterization of a gene responsible for the  $\text{Na}^+/\text{H}^+$  antiporter system of alkaliphilic *Bacillus* species strain C-125. *Mol. Microbiol.* **14**:939–946.
- Henikoff, S., and J. G. Henikoff. 1994. Protein family classification based on searching a database of blocks. *Genomics* **19**:97–107.
- Henner, D. J. 1990. Inducible expression of regulatory genes in *Bacillus subtilis*. *Methods Enzymol.* **185**:223–228.
- Hiramatsu, T., K. Kodama, T. Kuroda, T. Mizushima, and T. Tsuchiya. 1998. A putative multisubunit  $\text{Na}^+/\text{H}^+$  antiporter from *Staphylococcus aureus*. *J. Bacteriol.* **180**:6442–6448.
- Horton, R. M. 1996. *In vitro* recombination and mutagenesis of DNA. *Methods Mol. Biol.* **67**:141–149.
- Ireton, D. D., Z. Rudner, K. J. Siranosian, and A. D. Grossman. 1993. Integration of multiple developmental signals in *Bacillus subtilis* through Spo0A transcription factor. *Genes Dev.* **7**:283–294.
- Ito, M., A. A. Guffanti, B. Oudega, and T. A. Krulwich. 1999. *mrp*, a multi-gene, multifunctional locus in *Bacillus subtilis* with roles in resistance to cholate and to  $\text{Na}^+$  and in pH homeostasis. *J. Bacteriol.* **181**:2394–2402.
- Jack, D. L., M. L. Storms, J. H. Tchieu, I. T. Paulsen, and M. H. Saier, Jr. 2000. A broad-specificity multidrug efflux pump requiring a pair of homologous SMR-type proteins. *J. Bacteriol.* **182**:2311–2313.
- Kaback, H. R. 1971. Bacterial membranes. *Methods Enzymol.* **22**:99–120.
- Kosono, S., S. Morotomi, M. Kitada, and T. Kudo. 1999. Analyses of a *Bacillus subtilis* homologue of the  $\text{Na}^+/\text{H}^+$  antiporter gene which is important for pH homeostasis of alkaliphilic *Bacillus* sp. C-125. *Biochim. Biophys. Acta* **1409**:171–175.
- Kosono, S., Y. Ohashi, F. Kawamura, M. Kitada, and T. Kudo. 2000. Function of a principal  $\text{Na}^+/\text{H}^+$  antiporter, ShaA, is required for initiation of sporulation in *Bacillus subtilis*. *J. Bacteriol.* **182**:898–904.
- Krulwich, T. A., A. A. Guffanti, and M. Ito. 1999. pH tolerance in *Bacillus*: alkaliphiles vs non-alkaliphiles, p. 167–182. In D. J. Chadwick and G. Cardew (ed.), *Bacterial responses to pH*. Wiley, Chichester, England.
- Krulwich, T. A., M. Ito, R. Gilmour, D. B. Hicks, and A. A. Guffanti. 1998. Energetics of alkaliphilic *Bacillus* species: physiology and molecules. *Adv. Microb. Physiol.* **40**:410–438.
- Kudo, T., M. Hino, M. Kitada, and K. Horikoshi. 1990. DNA sequences required for the alkaliphily of *Bacillus* sp. strain C-125 are located close together on its chromosomal DNA. *J. Bacteriol.* **172**:7282–7283.
- Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193**:205–275.
- Masaoka, Y., Y. Ueno, Y. Morita, T. Kuroda, T. Mizushima, and T. Tsuchiya. 2000. A two-component multidrug efflux pump, EbrAB, in *Bacillus subtilis*. *J. Bacteriol.* **182**:2307–2310.
- Murphy, E., L. Huwyler, and M. D. D. Bastos. 1985. Transposon *Tn554*: complete nucleotide sequence and isolation of transposition defective and antibiotic-sensitive mutants. *EMBO J.* **4**:3357–3365.
- Padan, E., and T. A. Krulwich. 2000. Sodium stress, p. 117–130. In G. Storz and R. Hengge-Aronis (ed.), *Bacterial stress responses*. ASM Press, Washington, D.C.
- Putnoky, P., A. Kerez, T. Nakamura, G. Endre, E. Grosskopf, P. Kiss, and A. Kondorosi. 1998. The *pha* cluster of *Rhizobium meliloti* involved in pH adaptation and symbiosis encodes a novel type of  $\text{K}^+$  efflux system. *Mol. Microbiol.* **28**:1091–1101.